Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $40
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $39 to $40.
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $39 to $40.
